Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Researchers identify how proteasome takes care of unwanted, potentially toxic proteins

Researchers identify how proteasome takes care of unwanted, potentially toxic proteins

Gene variations can predispose people to chemotherapy-induced peripheral neuropathy

Gene variations can predispose people to chemotherapy-induced peripheral neuropathy

Duloxetine drug alleviates pain from chemotherapy

Duloxetine drug alleviates pain from chemotherapy

Medicare reimbursement cuts threaten access to care

Medicare reimbursement cuts threaten access to care

Inflammation and epigenetics: an interview with Dr Belkina and Dr Denis, Boston University School of Medicine

Inflammation and epigenetics: an interview with Dr Belkina and Dr Denis, Boston University School of Medicine

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Researchers identify role of Merlin in regulating integrity of axons

Researchers identify role of Merlin in regulating integrity of axons

Drugs that inhibit buildup of acylcarnitines may block axonal degeneration

Drugs that inhibit buildup of acylcarnitines may block axonal degeneration

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept fourth quarter revenue decreases to $0.1 million

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

NeuroMetrix fourth quarter total revenues decrease to $1.5 million

NeuroMetrix fourth quarter total revenues decrease to $1.5 million

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Diabetic peripheral neuropathy risk highlighted in children

Diabetic peripheral neuropathy risk highlighted in children

Boston College biologist to explore connection between peripheral neuropathy and HIV

Boston College biologist to explore connection between peripheral neuropathy and HIV

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Gait abnormalities found in diabetic neuropathy

Gait abnormalities found in diabetic neuropathy

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC